<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">SS</journal-id><journal-title-group><journal-title>Surgical Science</journal-title></journal-title-group><issn pub-type="epub">2157-9407</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/ss.2016.78053</article-id><article-id pub-id-type="publisher-id">SS-70155</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Clinic Pathological Profile of Neuroblastoma, Our Experience at Tertiary Care Hospital; Government Medical College Hospital Srinagar J &amp; K
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Zahida</surname><given-names>Akhter</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Shahnawaz</surname><given-names>Mansoor Shah</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Perveez</surname><given-names>Ahmad Malik</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Showkat</surname><given-names>Ahmad Kakroo</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>Sher-i-Kashmir Institute of Medical Sciences (SKIMS), Srinagar, India</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>drnawaz1008@gmail.com(SMS)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>03</day><month>08</month><year>2016</year></pub-date><volume>07</volume><issue>08</issue><fpage>368</fpage><lpage>373</lpage><history><date date-type="received"><day>29</day>	<month>June</month>	<year>2016</year></date><date date-type="rev-recd"><day>accepted</day>	<month>26</month>	<year>August</year>	</date><date date-type="accepted"><day>29</day>	<month>August</month>	<year>2016</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Introduction: Pediatric tumors account for a small proportion of all cancers; amongst them neuroblastoma is the most common solid tumor as well as malignant tumor. They have varied 
  clinical presentation. Recent advances in diagnostic methods and multidisciplinary treatment ap
  proach have resulted in early diagnosis, treatment, better prognosis and survival. Aims and Objectives: To study the clinical profile, histopathology, grading and correlate that with clinical diagnosis, efficacy of various investigations for early diagnosis, and management of neuroblastoma in our hospital. Material and Methods: A total of nine patients of neuroblastoma were studied from May 2013 to January 2015. All the nine patients were operated. Neuroblastoma was staged according to the International Neuroblastoma Staging system. Follow-up was carried in all the patients. Results: Two patients in our study were Stage 1, two were Stage 2A and 5 patients were 
  Stage 4S. In Stage 1, pre-operative chemotherapy was not given. Tumor was excised in toto. 
  Post-operatively, no adjuvant therapy was given. Patients are alive till date. In Stage 2A, patients were operated and received post-operative chemotherapy. One patient is alive and disease-free. Other patient died in post-op. period while on chemotherapy. Patients in Stage 4S were operated after receiving pre-op radiotherapy of 500 - 1000 radians and adjuvant chemotherapy. One patient expired in follow-up while four patients are still alive. We have achieved 100% survival rate in Stage 1, 50% in Stage 2 and 80% in Stage 4S.
 
</p></abstract><kwd-group><kwd>Child Hood Malignancies</kwd><kwd> Neuroblastoma</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Primary abdominal tumors, though relatively rare in children, attract considerable notice because of their serious prognosis, high cost of treatment and emotional and psychological trauma, both to parents and the patient. It is estimated that a child has one in five hundred chances of developing cancer during first fifteen years of life [<xref ref-type="bibr" rid="scirp.70155-ref1">1</xref>] . Cancer remains the leading cause of death, after accident for children 14 years of age and younger [<xref ref-type="bibr" rid="scirp.70155-ref2">2</xref>] .</p><p>The multidisciplinary approach to the care of oncological patients is essential. Majority of tumors in general and pediatric solid tumors in particular can successfully be managed through an orchestrated team approach.</p><p>The importance of pathological evaluation of tumor tissue could not be overlooked as the tumor histology was found to predict outcome.</p><p>Abdominal tumors can present with pain, vomiting, constipating or less commonly intestinal obstruction. It is not unusual for a child with abdominal mass to present because a family member notices a protuberant mass. The presentation of cancer in children resembles those of childhood conditions like infections particularly viral infection, urinary tract infection, gastro-esophageal reflex, malnutrition, constipation, lymphadenitis, glomerulonephritis and congenital urinary tract anomalies. Therefore deciding whether a child requires further investigation can be challenging [<xref ref-type="bibr" rid="scirp.70155-ref3">3</xref>] .</p><p>Recent advances in diagnostic methods and application of vigorous multidisciplinary treatment polices have made marked improvement in treating primary abdominal tumors of childhood, because if diagnosed earlier, these tumors are more responsive to treatment resulting in good survival and prognosis [<xref ref-type="bibr" rid="scirp.70155-ref4">4</xref>] .</p><p>Neuroblastoma is the most common solid tumor in childhood, as well as most common malignant tumor. 50% of cases occur in first two years and 75% occur by 5 years of age. Overall incidence is 10.95 per 1 million children younger than age of 15 years and 27.75 per 1 million children in the age group of 0 - 4 years.</p></sec><sec id="s2"><title>2. Aims and Objectives</title><p>To study the clinical profile of neuroblastoma at our hospital.</p><p>To study the efficacy of various investigations this would be helpful for early diagnosis, management and follow-up.</p><p>To study the outcome of this tumor after multimodality treatment in these cases in our set up.</p></sec><sec id="s3"><title>3. Material and Methods</title><p>The work has been undertaken to study the clinico-pathological profile of neuroblastoma in children who presented in the outpatient department of pediatric surgery government medical college Hospital, Srinagar from May 2013 to January 2015.</p><p>Records of all the patients admitted and operated up to January 2015 were analyzed and were summoned to attend the follow up clinic. A total of 09 patients were studied. Patients were selected randomly. Patients were followed throughout the study period from May 2013 to Jan 2015.</p><p>While evaluating the results of the study, relevant history was taken and examination was done. Routine investigations done included hematological, blood bio-chemistry, urine analysis and chest and abdominal radiographs. Specific investigations included, USG (ultrasonography) abdomen, FNAC (fine needle aspiration cytology) of the swelling, CECT (contrast enhanced computed tomography) abdomen and chest when required, MRI (magnetic resonance imaging), tumor markers, bone marrow biopsy, bone scan.</p><p>Post-operative follow up of the patients was done in all patients. The cases of primary abdominal tumors who were not amenable to surgery on clinical grounds or who needed pre or post-operative chemotherapy were planned in consultation with the Department of Medical Oncology SMHS (Shri Maharaja Hari Singh) Srinagar.</p><p>The treatment was planned according to stage of disease, clinical examination and investigative workup. The advanced stage disease needed pre-operative chemotherapy which was planned and consulted with oncology department of SMHS Hospital Srinagar. Post-operative treatment was planned as per operative findings, histopathology and presence or absence of residual disease.</p><p>Neuroblastoma was staged according to the International Neuroblastoma Staging system.</p><p>Post-operative follow up was carried out in all the patients in outpatient clinic of SMHS where a detailed note was made of physical findings with regard to the previous physical status. Investigations like USG or CECT were occasionally done whenever needed in which the presence or absence of residual disease or metastasis was noted. Follow up was carried out till the date of compilation of this work and figures are valid up to January 2015.</p></sec><sec id="s4"><title>4. Observations</title><p>This study included the clinic pathological profile of 9 patients of neroblastoma in pediatric age group that were admitted and managed over a period extending from May 2013 to January 2015 (Tables 1-9).</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Age distribution of neuroblastoma in pediatric age group</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Age in years</th><th align="center" valign="middle" >Neuroblastoma n = 9</th></tr></thead><tr><td align="center" valign="middle" >0 - 2</td><td align="center" valign="middle" >3 (33.3%)</td></tr><tr><td align="center" valign="middle" >2 - 4</td><td align="center" valign="middle" >3 (33.3%)</td></tr><tr><td align="center" valign="middle" >4 - 6</td><td align="center" valign="middle" >2 (22.2%)</td></tr><tr><td align="center" valign="middle" >6 - 8</td><td align="center" valign="middle" >1 (11.1%)</td></tr></tbody></table></table-wrap><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Symptoms in patients of neuroblastoma in our study</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Symptomology</th><th align="center" valign="middle" >No. of cases</th><th align="center" valign="middle" >% age</th></tr></thead><tr><td align="center" valign="middle" >Abdominal swelling</td><td align="center" valign="middle" >09</td><td align="center" valign="middle" >100</td></tr><tr><td align="center" valign="middle" >Pain abdomen</td><td align="center" valign="middle" >05</td><td align="center" valign="middle" >55.5</td></tr><tr><td align="center" valign="middle" >Fever</td><td align="center" valign="middle" >06</td><td align="center" valign="middle" >75</td></tr><tr><td align="center" valign="middle" >Vomiting</td><td align="center" valign="middle" >04</td><td align="center" valign="middle" >44.4</td></tr><tr><td align="center" valign="middle" >Pallor</td><td align="center" valign="middle" >06</td><td align="center" valign="middle" >75</td></tr><tr><td align="center" valign="middle" >Weight loss</td><td align="center" valign="middle" >02</td><td align="center" valign="middle" >22.2</td></tr><tr><td align="center" valign="middle" >Early fatigability</td><td align="center" valign="middle" >03</td><td align="center" valign="middle" >33.3</td></tr><tr><td align="center" valign="middle" >Loss of appetite</td><td align="center" valign="middle" >02</td><td align="center" valign="middle" >22.2</td></tr><tr><td align="center" valign="middle" >Metastatic manifestations (bladder and bowl incontinence)</td><td align="center" valign="middle" >01</td><td align="center" valign="middle" >11.1</td></tr><tr><td align="center" valign="middle" >Others</td><td align="center" valign="middle" >02</td><td align="center" valign="middle" >22.2</td></tr></tbody></table></table-wrap><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> USG findings in patients of neuroblastoma in our study</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Tumor characteristics</th><th align="center" valign="middle" >%</th></tr></thead><tr><td align="center" valign="middle" >Solid</td><td align="center" valign="middle" >05 (55.5%)</td></tr><tr><td align="center" valign="middle" >Cystic</td><td align="center" valign="middle" >02 (22.2%)</td></tr><tr><td align="center" valign="middle" >Loculated</td><td align="center" valign="middle" >01 (11.1%)</td></tr><tr><td align="center" valign="middle" >Liver involvement</td><td align="center" valign="middle" >02 (22.2%)</td></tr><tr><td align="center" valign="middle" >Spleen involvement</td><td align="center" valign="middle" >02 (22.2%)</td></tr><tr><td align="center" valign="middle" >Lymph node status</td><td align="center" valign="middle" >06 (66.6%)</td></tr><tr><td align="center" valign="middle" >Ascites</td><td align="center" valign="middle" >04 (44.4%)</td></tr></tbody></table></table-wrap><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> CECT findings in patients of neuroblastoma in our study</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Tumor characteristics</th><th align="center" valign="middle" >%</th></tr></thead><tr><td align="center" valign="middle" >Disease localized</td><td align="center" valign="middle" >03 (75%)</td></tr><tr><td align="center" valign="middle" >Extent demarcated</td><td align="center" valign="middle" >03 (75%)</td></tr><tr><td align="center" valign="middle" >Lymph node involvement</td><td align="center" valign="middle" >03 (75%)</td></tr><tr><td align="center" valign="middle" >Metastatic disease</td><td align="center" valign="middle" >01 (25%)</td></tr></tbody></table></table-wrap><table-wrap id="table5" ><label><xref ref-type="table" rid="table5">Table 5</xref></label><caption><title> Results of FNAC of accessible mass in patients of neuroblastoma</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >Neuroblastoma</th><th align="center" valign="middle" >No of cases of FNAC</th><th align="center" valign="middle" >Positive</th><th align="center" valign="middle" >% age</th><th align="center" valign="middle" >Negative</th><th align="center" valign="middle" >% age</th></tr></thead><tr><td align="center" valign="middle" >06</td><td align="center" valign="middle" >04</td><td align="center" valign="middle" >66.6</td><td align="center" valign="middle" >02</td><td align="center" valign="middle" >33.3</td></tr></tbody></table></table-wrap><table-wrap id="table6" ><label><xref ref-type="table" rid="table6">Table 6</xref></label><caption><title> Results of bone marrow aspiration cytology in patients of neuroblastoma</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >Neuroblastoma</th><th align="center" valign="middle" >No of cases investigated</th><th align="center" valign="middle" >Positive for malignant cells</th><th align="center" valign="middle" >%age</th><th align="center" valign="middle" >Negative</th><th align="center" valign="middle" >%age</th></tr></thead><tr><td align="center" valign="middle" >05</td><td align="center" valign="middle" >02</td><td align="center" valign="middle" >40</td><td align="center" valign="middle" >03</td><td align="center" valign="middle" >60</td></tr></tbody></table></table-wrap><table-wrap id="table7" ><label><xref ref-type="table" rid="table7">Table 7</xref></label><caption><title> Incidence of patients according to International Neuroblastoma Staging System for neuroblastoma in our study (n = 9)</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >International Staging System</th><th align="center" valign="middle" >No of cases</th><th align="center" valign="middle" >% age</th></tr></thead><tr><td align="center" valign="middle" >Stage 1</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >22.2</td></tr><tr><td align="center" valign="middle" >Stage 2A</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >22.2</td></tr><tr><td align="center" valign="middle" >Stage 2B</td><td align="center" valign="middle" >ND</td><td align="center" valign="middle" >ND</td></tr><tr><td align="center" valign="middle" >Stage 3</td><td align="center" valign="middle" >ND</td><td align="center" valign="middle" >ND</td></tr><tr><td align="center" valign="middle" >Stage 4</td><td align="center" valign="middle" >ND</td><td align="center" valign="middle" >ND</td></tr><tr><td align="center" valign="middle" >Stage 4S</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >55.5</td></tr></tbody></table></table-wrap><table-wrap id="table8" ><label><xref ref-type="table" rid="table8">Table 8</xref></label><caption><title> Operative findings in patients of neuroblastoma (n = 9)</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Operative findings</th><th align="center" valign="middle" >No of cases</th><th align="center" valign="middle" >% age</th></tr></thead><tr><td align="center" valign="middle" >Tumor localized with complete excision and lymphadenectomy Nodes and tumor margins negative</td><td align="center" valign="middle" >03</td><td align="center" valign="middle" >33.3</td></tr><tr><td align="center" valign="middle" >Tumor localized with lymph node negative but incomplete gross excision</td><td align="center" valign="middle" >02</td><td align="center" valign="middle" >22.2</td></tr><tr><td align="center" valign="middle" >Tumor localized, completely excised but liver metastasis present</td><td align="center" valign="middle" >02</td><td align="center" valign="middle" >22.2</td></tr><tr><td align="center" valign="middle" >Tumor localized, completely excised but with marrow involvement</td><td align="center" valign="middle" >02</td><td align="center" valign="middle" >22.2</td></tr></tbody></table></table-wrap><p>66.6% of patients were male and 33.3% female. 75% of patients were from rural area and 25% from urban.</p><p>Abdominal swelling was the constant finding in all cases of neuroblastoma. Diarrhoea was due to the release of vasoactive intestinal polypeptide. Metastatic manifestation was late presentation of disease.</p><p>On physical examination 77.7% patients had pallor and 11% had oedema. Distention and visible lump was consistent finding in all the patients, flank fullness in 55.5%, umbilical shift in 22.2% and ascites in 22.2%.</p><p>22.2% patients had hemoglobin below 6 g∙m %, 44.4% between 6 - 10 g∙m % and 22.2% had 10.1 and above.</p><p>All the patients of neuroblastoma underwent surgery in our study.</p><p>In our study we studied nine patients of neuroblastoma. Two patients were Stage 1 (22.2%), two patients were Stage 2A (22.2%) and 5 patients were Stage 4S (55.5%) (<xref ref-type="fig" rid="fig1">Figure 1</xref>).</p></sec><sec id="s5"><title>5. Discussion</title><p>Present study was conducted in Pediatric division of Department of Surgery, government medical Hospital, Srinagar. In our study we studied nine cases of neuroblastoma. These patients were staged according to International Staging System of neuroblastoma.</p><p>Two patients in our study were Stage 1, two were Stage 2A and 5 patients were Stage 4S.</p><table-wrap id="table9" ><label><xref ref-type="table" rid="table9">Table 9</xref></label><caption><title> Adjuvant therapy and follow up in neuroblastoma</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Stage</th><th align="center" valign="middle" >No of patients</th><th align="center" valign="middle" >Pre-operative chemo/radio therapy</th><th align="center" valign="middle" >Surgery done</th><th align="center" valign="middle" >Post-operative chemotherapy</th><th align="center" valign="middle" >Post-operative radiotherapy</th><th align="center" valign="middle" >Disease free survival</th><th align="center" valign="middle" >%age disease free survival</th></tr></thead><tr><td align="center" valign="middle" >1</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >Not given</td><td align="center" valign="middle" >Done in both</td><td align="center" valign="middle" >No</td><td align="center" valign="middle" >No</td><td align="center" valign="middle" >Both are alive and disease free</td><td align="center" valign="middle" >100</td></tr><tr><td align="center" valign="middle" >2A</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >Not given</td><td align="center" valign="middle" >Done in both</td><td align="center" valign="middle" >Vincristine, Cyclophosphamide, Cisplatin, Doxorubicin, Etoposide.</td><td align="center" valign="middle" >No</td><td align="center" valign="middle" >One patient died in post-operative period, one still alive</td><td align="center" valign="middle" >50</td></tr><tr><td align="center" valign="middle" >4S</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >Pre-operative radiotherapy 500 - 1000 rads</td><td align="center" valign="middle" >Done in all</td><td align="center" valign="middle" >Cisplatin, Cyclophosphamide Adriamycin, Decarbazine</td><td align="center" valign="middle" >No</td><td align="center" valign="middle" >Four patients alive, 1 died</td><td align="center" valign="middle" >80</td></tr></tbody></table></table-wrap><fig id="fig1"  position="float"><label><xref ref-type="fig" rid="fig1">Figure 1</xref></label><caption><title> Graphical representation of % survival in different stages of neuroblastoma in our study</title></caption><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/7-2301052x7.png"/></fig><p>In Stage 1, no pre op. chemotherapy was given. Tumor was excised in total. Post-operatively no adjuvant therapy was given. Both patients are alive till date.</p><p>In Stage 2A, patients were operated and received post-operative chemotherapy. One patient is alive and disease free. Other patient died in post-op. period while on chemotherapy.</p><p>Patients in Stage 4S were operated after receiving pre-op radiotherapy of 500 - 1000 rads and adjuvant chemotherapy. One patient expired in follow up while four patients are still alive.</p><p>We have achieved 100% survival rate in Stage 1, 50% in Stage 2 and 80% in Stage 4S.</p></sec><sec id="s6"><title>6. Conclusions</title><p>Pediatric tumors form a small proportion of all cancers; however, they are important in understanding the importance of neoplastic growth, evolution of cancer therapy and its social impact is much more than anticipated; besides it results in loss of many more productive years of life. Gratifying advance in the treatment of pediatric cancers for the past three decades has resulted in decrease in annual mortality by 36%.</p><p>However, much inference about survival in pediatric malignancies cannot be committed upon because of the less number of patients which were studied and followed up only for a short period of time.</p></sec><sec id="s7"><title>Cite this paper</title><p>Zahida Akhter,Shahnawaz Mansoor Shah,Perveez Ahmad Malik,Showkat Ahmad Kakroo, (2016) Clinic Pathological Profile of Neuroblastoma, Our Experience at Tertiary Care Hospital; Government Medical College Hospital Srinagar J &amp; K. Surgical Science,07,368-373. doi: 10.4236/ss.2016.78053</p></sec><sec id="s8"><title>NOTES</title></sec></body><back><ref-list><title>References</title><ref id="scirp.70155-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Oldham, K.T., Colomboani, P.M. and Foglia, R.P. (1997) Surgery of Infants and Children. Scientific Principles and Practice, Lippincott-Raven, Philadelphia, 537-548, 549-565.</mixed-citation></ref><ref id="scirp.70155-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Ghai, O.P., Gupta, P. and Paul, V.K. (2000) Malignancies in Childhood, Essential Paediatrics. 5th Edition, 462-474.</mixed-citation></ref><ref id="scirp.70155-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Young, G., Toretsky, J.A., et al. (2000) Recognition of Common Childhood Malignancies. American Family Physician, 61, 2144-2151.</mixed-citation></ref><ref id="scirp.70155-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Malpas, J.S. and Freeman, J.E. (1974) Blood and Neoplastic Diseases: Solid Tumours in Children. British Medical Journal, 4, 710-713. http://dx.doi.org/10.1136/bmj.4.5946.710</mixed-citation></ref></ref-list></back></article>